Scientific Reports · 2022 · 14 citations · 28 references
MedicineOncologyUrologyBiosensorsMolecular DiagnosticsMolecular OncologyAptamer-based BiosensorsCancer BiomarkersCancer Molecular DiagnosticsMolecular BiomarkersNucleic Acid Amplification TestingSignal Amplification StrategiesAptamer-based AssaysAptamer-based BiosensingAptamer-based DetectionAptamer-based NanobiosensorsAptamer-based ProbesAssayDna Aptamer-based BiosensorsHybridization Chain Reaction
= 8.26 nM) aptamer, and a sensitive and specific enzyme-linked oligonucleotide assay (ELONA) for rapid and sensitive colorimetric detection of bladder and prostate cancer biomarker EN2 in urine. The assay relies on an aptamer-mediated hybridization chain reaction (HCR) to generate DNA nanostructures that bind to EN2 and simultaneously amplify signals. The assay can be performed within 2.5 h, and has a limit of detection of 0.34 nM in buffer and 2.69 nM in artificial urine. Moreover, this assay showed high specificity as it did not detect other urinary proteins, including biomarkers of other cancers. The proposed ELONA is inexpensive, highly reproducible, and has great chemical stability, so it may enable development of a simple, sensitive and accurate diagnostic tool to detect bladder and prostate cancers early.
28